TRODELVY
Google image searchProduct monograph
Active ingredient
sacituzumab govitecan, 180 MG/VIAL
DIN: 02520788
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription
Company: GILEAD SCIENCES CANADA INC
Date: 22-NOV-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FX — Other monoclonal antibodies and antibody drug conjugates (ATC, ATC/DDD)
- L01FX17 — SACITUZUMAB GOVITECAN (ATC/DDD)
Pharmaceutical standard: MFR
